1 – 10 of 87
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2018
- The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer
- 2017
- Radiotherapy access in Belgium: How far are we from evidence-based utilisation?
- The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy
- 2016
- Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: a single-arm phase II study (EORTC-08061)
- Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer
- Melanoma burden by melanoma stage : assessment through a disease transition model
- Cost-effectiveness analysis in melanoma detection: a transition model applied to dermoscopy
- 2015
- Responding to the cancer crisis: expanding global access to radiotherapy: a Lancet Oncology Commission
- Immunohistochemical analysis of CD70 expression in 95 cases of squamous cell carcinoma of the head and neck: correlation with clinicopathological variables and identification of a novel therapeutic target
- Maintenance pazopanib versus placebo in non-small cell lung cancer patients non-progressive after first line chemotherapy: a double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)